Sir, Martell & Jacobs' in their article (October 1986 issue) suggest that early surgery offers 'the only realistic chance of survival' in patients developing an acute abdomen during the pancytopenic period following chemotherapy for leukaemia. This claim is made despite the fact that 3 out of 5 patients who underwent surgery died within 14 days post-operatively and all three patients who died received high-dose cytosine arabinoside. We present here our experience of the conservative management of acute abdominal problems after high-dose cytosine arabinoside treatment for leukaemia and lymphoma.
Between Table I ).
Martell & Jacobs cite a number of studies which suggest that surgical intervention has a role to play in leukaemic patients who are neutropenic following chemotherapy. However, none ofthese studies was randomized and as pointed out by several authors the patients treated conservatively were more severely ill and had lower performance status than those who underwent surgery. Such patient selection would be bound to bias the results of any retrospective analysis as to the merits ofsurgery as opposed to conservative management for these patients.
We report here a 50% survival rate for patients who develop an acute abdomen after high-dose cytosine arabin- 
